RARE CASE OF CD10+CD23+ HAIRY CELL LEUKEMIA WITH LEUKOCYTOSIS. CASE REPORT AND LITERATURE REVIEW
DOI:
https://doi.org/10.15407/exp-oncology.2025.01.091Keywords:
hairy cell leukemia, leukocytosis, CD10+CD23+ aberrant expression, BRAF V600E mutation, case reportAbstract
A rare case of hairy cell leukemia with CD10+CD23+ expression and leukocytosis is described. The key point marker for hairy cell leukemia is the presence of the BRAF V600E mutation regardless of the leukocyte count and atypical aberrant CD10+ or CD23+ expression. The presented clinical case report is important for understanding the biology of hairy cell leukemia and emphasizes the role of molecular genetic testing in atypical morpho-phenotyping disease presentation.
References
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748. https://doi.org/10.1038/ s41375-022-01620-2
Troussard X, Maître E, Cornet E. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
Am J Hematol. 2022;97(2):226-236. https://doi.org/10.1002/ajh.26390
Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treat- ment and follow-up. Annals Oncol. 2015;26(5):100-107. https://doi.org/10.1093/annonc/mdv200
Kryachok IA, Titorenko IB. Hairy cell leukemia: a literature review and a clinical case. Clin Oncology. 2019;9(3):140-
https://doi.org/10.32471/clinicaloncology.2663-466X.40.23039 (in Ukrainian).
Starchenko II, Filenko BM, Royko NV, et al. Synchronous hairy cell leukemia and hepatocellular carcinoma: a case report. Exp Oncol. 2022;44:259-262. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18302
Adley BP, Sun X, Shaw JM, Variakojis D. Hairy cell leukemia with marked lymphocytosis. Arch Pathol Lab Med.
;127(2):253-254. https://doi.org/10.5858/2003-127-253-HCLWM
Almakadi M, Akram MR, Aldhafeeri D, et al. Hairy cell leukemia with severe leukocytosis. Blood. 2023;142(S1):4426. https://doi.org/10.1182/blood-2023-187034
Kumar L, Bharti R, Kumar H, Kaushik N. Hairy cell leukaemia — a rare case presented with leukocytosis. Natl J Lab Med. 2021;10(2):PC01-PC02. https://doi.org/10.7860/NJLM/2021/44364:2472
Chen YH, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol. 2006;125:251-259. https://doi.org/10.1309/PMQXVY619Q8Y43AR
Wang L, Tadros AS, Hoh CK, Wang HY. CD10-positive hairy cell leukemia involving multiple deep lymph nodes.
Clin Lymphoma Myeloma Leuk. 2016;16:e51-e51-3. https://doi.org/10.1016/j.clml.2016.02.041
Zhao Hl, Cui Hh, Jin Lf, et al. CD103-CD23+ classical hairy cell leukemia: a case report and review of the literature.
Medicine. 2021; 100:51(e28262). http://dx.doi.org/10.1097/MD.0000000000028262
Tsuber V, Kadamov Y, Brautigam L, et al. Mutations in cancer cause gain of cysteine, histidine, and tryptophan at the expense of a net loss of arginine on the proteome level. Biomolecules. 2017;7(3):49. https://doi.org/10.3390/ biom7030049.
Garza-Ledezma MA, Tellez-Hinojosa CA, González-López EE, D. Gómez-Almaguer D. Hairy cell leukemia, an uncommon B-cell lymphoid neoplasia. Medicina Universitaria. 2016;18(70):34-41. http://dx.doi.org/10.1016/j. rmu.2015.12.002
Schrek R, Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of nor- mal lymph nodes. Blood. 1966;27:199-211.
Parry-Jones N, Joshi A, Forconi F, et al. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020;191:730-737. https://doi.org/10.1111/bjh.17055
Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/ refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14:35. https://doi.org/10.1186/s13045-020-01004-y
Bohn J-P, Dietrich S. Treatment of classic hairy cell leukemia: targeting minimal residual disease beyond cladribine.
Cancers. 2022;14(4):956. https://doi.org/10.3390/cancers14040956
Robak T, Janus A, Jamroziak K, et al. Vemurafenib and rituximab in patients with hairy cell leukemia previously treated with moxetumomab pasudotox. J Clin Med. 2021;10:2800. https://doi.org/10.3390/jcm10132800
Skrypnyk I, Maslova G, Lymanets T, Gusachenko I. L-arginine is an effective medication for prevention of en- dothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Exp Oncol. 2017;39:308-311. https://doi.org/10.31768/2312-8852.2017.39(4):308-311
Janowska A, Janus A, Kociszewski K, Robak T. New therapeutic options for hairy cell leukemia. Acta Haematol Pol. 2022;53:39-47. https://doi.org/10.5603/AHP.a2021.0095
Skrypnyk I, Maslova G, Lymanets T, Gusachenko I. How to improve quality of life in patients with acute leuke- mia and comorbid ischemic heart disease treated with anthracyclinebased induction chemotherapy. Exp Oncol. 2019;41:353-356. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13906
Anghelina M, Naughton MJ, Zhao Q, et al. Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia. Leuk Res. 2022;120:106919. https://doi.org/10.1016/j.leukres.2022.106919
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
